Biohaven migraine drug partnered with Pfizer lands twin European approvals

[cafead]

via The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for Biohaven, it's also a win for Pfizer, which holds rights to commercialize the drug outside of the U.S.

article source